Biogen

US · BIIB #623 by market cap Listed 1970

222.15 -0.74 -0.33%

Live - 5344 symbols - heartbeat 521s ago · 2026-10-08 04:46

Pre-market 222.80 +0.29%

After-hours 222.15 0.00%

Overnight 221.74 -0.18%

Market cap: 32.82B
P/E (TTM): 39.46
P/B: 1.74
EPS: 8.79
Div yield: 0.00%
52W pos: 91%

Reader sentiment Are you bullish or bearish on BIIB?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Good

Altman Z-Score is 3.58, above the 3.0 "safe zone" threshold.
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +2.22% YoY

Margins

Gross margin: 75.69%
Operating margin: 24.96%
Net margin: 13.07%

Key ratios & quality

Altman Z-Score: 3.58

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	13.45B	14.38B	13.44B	10.98B	10.17B	9.84B	9.68B	9.89B
Gross profit	11.64B	12.42B	11.64B	8.87B	7.90B	7.30B	7.37B	7.49B
Selling & admin expenses	2.11B	2.37B	2.50B	2.67B	2.40B	2.55B	2.40B	2.43B
Research & development	2.60B	2.28B	3.99B	2.50B	2.23B	2.45B	1.98B	1.78B
Operating profit	6.00B	7.04B	4.45B	2.81B	2.90B	1.85B	2.28B	2.47B
Pretax profit	5.90B	7.13B	5.05B	1.75B	3.59B	1.30B	1.91B	1.56B
Tax	1.43B	1.16B	992.30M	52.50M	632.80M	135.30M	273.80M	263.60M
Net profit	4.47B	5.89B	4.06B	1.73B	2.96B	1.16B	1.63B	1.29B
Basic EPS	22	31	25	10	21	8	11	9
Diluted EPS	21.58	31.42	24.80	10.40	20.87	7.97	11.18	8.79

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	2.43B	2.65B	2.53B	2.28B	2.48B	2.74B
Gross profit	1.80B	2.04B	1.86B	1.78B	1.82B	1.96B
Selling & admin expenses	572.50M	583.80M	594.80M	682.50M	607.30M	709.70M
Research & development	434.10M	399.00M	436.10M	509.40M	539.00M	529.60M
Operating profit	625.20M	851.80M	606.50M	385.50M	459.80M	482.80M
Pretax profit	311.20M	744.00M	557.30M	-56.00M	377.70M	132.40M
Tax	70.70M	109.20M	90.80M	-7.10M	58.20M	34.90M
Net profit	240.50M	634.80M	466.50M	-48.90M	319.50M	97.50M
Basic EPS	2	4	3	0	2	1
Diluted EPS	1.64	4.33	3.17	-0.33	2.15	0.66

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	7.64B	8.38B	6.89B	7.86B	9.79B	6.86B	7.46B	8.97B
Cash & ST investments	3.54B	4.48B	2.61B	3.80B	4.89B	1.05B	2.38B	3.82B
Inventory	929.90M	804.20M	1.07B	1.35B	1.34B	2.53B	2.46B	2.17B
Total assets	25.29B	27.23B	24.62B	23.88B	24.55B	26.84B	28.05B	29.44B
Total current liabilities	3.30B	4.86B	3.74B	4.30B	3.27B	3.43B	5.53B	3.35B
Short-term debt	--	1.50B	--	999.10M	--	150.00M	1.75B	--
Long-term debt	5.94B	4.46B	7.43B	6.27B	6.28B	6.79B	4.55B	6.29B
Total liabilities	12,257,300,000.00	13,895,200,000.00	13,932,800,000.00	12,917,600,000.00	11,165,700,000.00	12,045,400,000.00	11,333,300,000.00	11,182,700,000.00
Total equity	13.03B	13.34B	10.69B	10.96B	13.39B	14.80B	16.72B	18.26B
Retained earnings	16.26B	16.46B	13.98B	13.91B	16.47B	17.63B	19.26B	20.55B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	7.63B	7.97B	8.94B	8.97B	9.19B	7.31B
Cash & ST investments	2.60B	2.76B	3.96B	3.82B	4.28B	1.29B
Inventory	2.27B	2.27B	2.21B	2.17B	1.95B	2.38B
Total assets	28.03B	28.33B	29.21B	29.44B	29.48B	32.09B
Total current liabilities	5.30B	3.18B	3.29B	3.35B	3.00B	3.92B
Short-term debt	1.75B	--	--	--	--	800.00M
Long-term debt	4.55B	6.28B	6.29B	6.29B	6.29B	7.29B
Total liabilities	11,054,400,000.00	10,696,200,000.00	11,000,000,000.00	11,182,700,000.00	10,831,400,000.00	13,238,600,000.00
Total equity	16.98B	17.63B	18.21B	18.26B	18.65B	18.85B
Retained earnings	19.50B	20.14B	20.60B	20.55B	20.87B	20.97B

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	6.19B	7.08B	4.23B	3.64B	1.38B	1.55B	2.88B	2.20B
Depreciation & amortization	650.50M	464.70M	457.20M	487.70M	518.40M	494.80M	673.20M	779.90M
Free cash flow	5.30B	6.41B	3.68B	3.35B	1.14B	1.24B	2.52B	1.97B
Dividends paid	--	--	--	--	--	--	--	--
Stock buybacks / issuance	-4.35B	-5.87B	-6.68B	-1.80B	-750.00M	--	--	--
Ending cash balance	1.22B	2.91B	1.33B	2.26B	3.42B	1.05B	2.38B	3.01B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	259.30M	160.90M	1.27B	511.90M	645.50M	448.90M
Depreciation & amortization	183.20M	194.30M	202.20M	200.20M	204.40M	236.10M
Free cash flow	212.20M	134.30M	1.22B	401.70M	559.30M	308.00M
Dividends paid	--	--	--	--	--	--
Stock buybacks / issuance	--	--	--	--	--	--
Ending cash balance	2.60B	2.76B	3.86B	3.01B	3.38B	1.29B

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	34.54	44.64	33.28	14.41	25.08	8.24	10.36	7.39
ROA %	18.11	22.42	15.43	6.42	12.58	4.52	5.95	4.50
ROIC %	23.97	29.59	22.56	9.42	16.94	5.36	7.86	6.08
5-year avg ROE %	30.97	33.85	33.48	29.48	30.39	25.13	18.27	13.10
EBIT margin %	45.34	50.86	39.20	18.20	37.73	15.70	22.29	18.44
FCF / sales %	39.41	44.58	27.36	30.46	11.22	12.56	26.00	19.91
Current ratio	2.32	1.72	1.84	1.83	2.99	2.00	1.35	2.68
Quick ratio	1.83	1.43	1.32	1.34	2.15	0.92	0.77	1.70
Debt / assets	23.47	23.38	31.80	31.84	26.94	27.34	23.64	22.34
LT debt / equity	45.53	36.51	73.16	60.61	49.37	48.57	29.20	36.03
Interest coverage	30.41	39.03	23.69	7.88	15.57	6.25	8.61	6.82
Revenue CAGR (3Y) %	7.72	7.89	3.08	-6.54	-10.89	-9.89	-4.13	-0.94
Net income CAGR (3Y) %	7.70	16.72	16.36	-29.45	-19.72	-33.79	1.60	-24.85
FCF CAGR (3Y) %	17.59	18.42	12.43	-14.23	-43.74	-30.48	-9.06	19.95

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	9.19	9.13	9.31	7.39	7.70	4.58
ROA %	5.42	5.55	5.59	4.50	4.77	2.76
ROIC %	7.08	7.15	7.55	6.08	6.32	3.68
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	20.31	20.51	21.50	18.44	19.10	12.93
FCF / sales %	23.39	18.47	22.47	19.91	23.31	24.83
Current ratio	1.44	2.50	2.72	2.68	3.06	1.87
Quick ratio	0.87	1.52	1.77	1.70	2.03	0.94
Debt / assets	23.62	23.28	22.56	22.34	22.26	26.04
LT debt / equity	28.70	37.40	36.19	36.03	35.18	40.08
Interest coverage	8.27	8.12	8.32	6.82	6.90	4.55
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Diversified

Revenue from anti-CD20 therapeutic programs is the largest reported line at 18.77% of revenue, across 10 reported segments.
No single line clears half of revenue; TYSABRI is next at 16.48%, spreading the business across more than one real driver.

Revenue breakdown most recent period

Business

Revenue from anti-CD20 therapeutic programs18.77%

TYSABRI16.48%

SPINRAZA14.69%

Other14.21%

Contract manufacturing, royalty and other revenue8.86%

VUMERITY7.18%

AVONEX6.21%

SKYCLARYS6.14%

BENEPALI3.90%

SYFOVRE3.56%

Quote time 2026-10-08 04:46:37 · For reference only, not investment advice and not tailored to your situation.